Phase A — Understand the business
Lens 1 · Company Overview
Albemarle is the Western world's largest lithium producer and a specialty-chemicals company headquartered in Charlotte, NC. After a multi-year portfolio reshaping it runs on two go-forward reportable segments plus a divesting third:
- Energy Storage — lithium carbonate, hydroxide and specialty lithium salts for EV and grid-storage batteries. This is the franchise and the swing factor: FY2025 net sales $2,710.0M, 52.7% of total.
- Specialties — bromine (flame retardants, oilfield, water treatment), lithium specialties (pharma, greases, organometallics) and cesium. The cash-stable ballast: FY2025 net sales $1,366.4M, 26.6% of total.
- Ketjen — refining/petrochemical catalysts (FCC + hydroprocessing). Being exited: Albemarle sold its 51% controlling stake to KPS Capital Partners for ~$547M, closing 2026-03-02. FY2025 net sales were $1,066.3M but Ketjen leaves the consolidated picture in FY2026 (Q1'26 already shows it pulled out of segment reporting).
Business model in plain terms. ALB digs/pumps lithium-bearing material from a small number of world-class resources, converts it to battery-grade chemicals at owned plants, and sells under a contract book that is ~40% of salts volume on long-term agreements with the balance exposed to spot/index pricing. That ~60% index exposure is why the stock trades as a lithium-price proxy. Revenue is a price × volume function where the company controls volume and cost but is a price-taker on the larger commodity — management says so explicitly: "we're not able to predict the lithium price… we have to be able to compete through the bottom of the cycle" (Kent Masters).
Main customers: battery makers and cathode producers across the EV/ESS chain — LG Energy Solution, Panasonic, CATL, and OEM/cathode counterparties (specific ALB offtake names are not cleanly disclosed in public sources; the customer roster is concentrated among the tier-1 cell/cathode makers). Suppliers/partners: ALB's "suppliers" are largely its own JV resources (see Lens 2). Competitors: SQM, Tianqi, Ganfeng, Pilbara Minerals, and — newly — Rio Tinto Lithium (the former Arcadium, acquired by Rio for $6.7B, March 2025).
Contract structure / key terms. Mixed: ~40% of Energy Storage salts volume on long-term agreements (some with floors/ceilings), ~60% index-linked. Specialties is more conventional B2B chemicals pricing. A customer prepayment received January 2025 materially flattered FY2025 operating cash flow.
Lens 2 · Supply Chain
Map: resource (brine / hard rock) → conversion → battery-grade chemical → cell/cathode maker → OEM. Every named node:
Upstream resources (the crown jewels):
- Salar de Atacama, Chile (brine) — among the lowest-cost lithium sources on earth. Operated by Albemarle Ltda. under a CORFO exploitation contract running to 2043, 82kt/yr authorized quota. Single largest, lowest-cost source.
- Silver Peak, Nevada (brine) — the only operating US lithium production; small.
- Greenbushes, Western Australia (hard rock / spodumene) — the best spodumene resource in the world. Held via Talison Lithium: Albemarle 49% / TLEA 51%, where TLEA = Tianqi 26.01% + IGO 24.99%. ALB takes 50% of offtake. Lowest-quartile cost; the structural moat.
- Wodgina, Western Australia (hard rock) — via MARBL JV, now 50% Albemarle / 50% Mineral Resources (rebalanced from 60/40 in 2023). Higher-cost than Greenbushes.
Conversion (the capacity question):
- Meishan, China — reached full nameplate 50ktpy in H1 2025, serving Asia. The growth lever that worked.
- Kemerton, Western Australia — the growth lever that didn't: Trains 3 & 4 cancelled (2024), Train 2 to care-and-maintenance, Train 1 idled into care-and-maintenance (announced 2025). A material capital-discipline scar.
- Plus La Negra (Chile), Kings Mountain/Silver Peak (US), Xinyu/Chengdu (China).
Chokepoints / single-source dependencies:
- Chile concentration — the lowest-cost tonnes sit under a single sovereign contract with an escalating royalty (Lens 12/13). The bottleneck is the moat and is the risk.
- JV control — Greenbushes (ALB is the minority 49% holder) and Wodgina are co-controlled with Chinese (Tianqi) and Australian (MinRes, IGO) partners. ALB does not unilaterally control its best resources.
- Conversion-vs-resource mismatch — the spodumene-to-hydroxide converter step is where Chinese lepidolite/converter overcapacity sets the marginal price (Lens 5/13).
This lens passes the "names or it didn't happen" test: Talison, TLEA, Tianqi, IGO, MinRes, CORFO, Codelco (adjacent), KPS, Axens, Rio Tinto are all named.
Lens 3 · Competitive Advantages (moats)
The moat is geological, not commercial. ALB sells a commodity — there is no brand, switching cost, or network effect at the molecule level (battery-grade lithium carbonate is fungible). The durable advantage is position on the cost curve:
- Lowest-quartile cost at Atacama brine and Greenbushes spodumene. Talison/Greenbushes AISC is reported around the ~$7,000/t LCE floor of the hard-rock cost curve (vs up to ~$12,000/t for marginal spodumene). Brine sits even lower. This is the single most important fact about ALB: at a $10/kg (~$10,000/t) market price that bankrupts marginal converters, ALB's best tonnes still generate cash.
- Scale + integration — owned conversion network lets ALB capture the resource-to-chemical spread; Greenbushes spodumene converts directly to hydroxide.
- Resource life / optionality — multi-decade reserves at the lowest-cost assets; an embedded call on the next price up-cycle.
Bargaining power: weak over price (price-taker on ~60% of volume), moderate over customers (qualified battery-grade supply with multi-year quals is sticky once designed-in), structurally constrained over its own resources by the JV/sovereign arrangements. The honest framing: ALB has a cost moat, not a pricing moat. It survives the cycle better than peers; it does not control the cycle.
Lens 4 · Segments
FY2025 vs FY2024, all figures ``:
| Segment | FY25 net sales | FY24 net sales | YoY | FY25 adj EBITDA | FY24 adj EBITDA | YoY |
|---|
| Energy Storage | $2,710.0M | $3,015.1M | −10.1% | $697.2M | $757.5M | −8.0% |
| Specialties | $1,366.4M | $1,326.0M | +3.0% | $275.7M | $228.5M | +20.7% |
| Ketjen (divesting) | $1,066.3M | $1,036.4M | +2.9% | $150.4M | $131.1M | +14.7% |
| Corporate | — | — | — | $(25.4)M | $22.7M | NM |
| Total | $5,142.7M | $5,377.5M | −4.4% | $1,098.0M | $1,139.8M | −3.7% |
Read: FY2025 was a price recession masked by volume growth. Energy Storage volume +14% to 235kt LCE (above guidance) yet sales fell 10% — the entire gap is price. Specialties was the hero (+21% EBITDA on cost-out and mix), proving the bromine ballast does its job when lithium is down. The trend inflected hard in Q1'26 (Lens 5): Energy Storage sales +70% as the lithium price recovered.
Geography: ALB skews to Asia-Pacific demand (China conversion, Asian cell makers) with resources in Chile + Australia and specialty/bromine in the US + Jordan (Dead Sea). Precise geographic revenue split n/a (would require the 10-K segment note; ingest-filing.ts not run per wave constraint).
Phase B — Measure performance
Lens 5 · Earnings Result (latest print = Q1 FY2026, reported 2026-05-06)
The most important data point in this dossier: the cycle turned. Q1 2026 vs Q1 2025, all ``:
- Net sales $1,428.7M, +32.7% — Energy Storage volumes +14%, price +51%; Specialties volumes +7%, price +2%. Ketjen divestiture cut sales ~4%.
- GAAP net income $319.1M (vs $41.3M) — $2.34/diluted share to common (vs ~$0.00).
- Adjusted EBITDA $663.8M, +148.5% — Energy Storage adj EBITDA $551.4M, +196% (a ~62% segment EBITDA margin on the price spike + spodumene inventory timing); Specialties $76.1M, +30%.
- Adjusted diluted EPS $2.95 (vs −$0.18) — a $3.13/share swing.
- FCF $248M, capex $99M; FY2026 capex guide $550–600M (held).
- Balance sheet repaired: paid down $1.3B of debt in Q1'26; long-term debt $1,807.2M (from $3,119.5M at YE25); net debt/adj-EBITDA ~1.0x (credit-agreement basis); liquidity ~$2.7B ($1.1B cash). Funded partly by ~$648M net cash from Ketjen + Eurecat divestitures.
Contrast with FY2025 (the trough), ``:
- FY2025 net sales $5,142.7M (−4.4%); GAAP net loss attributable to ALB $(510.6)M; to common $(677.4)M after $166.8M mandatory-convert preferred dividends.
- FY2025 included a $181.1M goodwill impairment and a $245.6M long-lived-asset impairment.
- Q4'25 alone: net sales $1,428.0M (+16%), GAAP net loss $(414.2)M / $(3.87)/sh, adjusted loss $(0.53)/sh — distorted by a valuation allowance on the entire US deferred-tax asset (Q4 effective tax rate −55.2%) and the Ketjen write-down.
- FY2025 cash flow was strong despite the loss: OCF $1.3B (>100% conversion), FCF $692M, capex $590M (−65% YoY) — the cost/cash program ($450M of improvements vs a $300–400M target) is real and is the bull's "they fixed the cost base before the price came back" point.
Market reaction context: the stock has rallied from a ~$110 trough (late 2024) to ~$159–170 (June 2026) as the cycle turned. What the tape rewards here is unambiguous: the lithium spot price (see Lens 8).
Lens 6 · Earnings Calls (sentiment trend)
No transcripts in the research layer; sentiment read from release language + coverage ``. The arc across the last ~4–5 calls:
- 2024 (deep trough): language dominated by "preserve, reduce, optimize" — capex cuts, headcount, project deferrals, the $2.2B mandatory-convert raise. Defensive.
- FY2025 calls: pivot to "execution amid dynamic market conditions," "cost and productivity," "financial flexibility," "world-class resources." Still cautious but emphasising self-help and through-cycle competitiveness.
- Q1 2026 call: notably more confident — "strong start," "net sales and adjusted EBITDA up year over year," debt paydown, "long-term volume and earnings growth" — while explicitly keeping enterprise guidance unchanged and flagging "supply chain disruptions in the Middle East" (bromine/Jordan cost pressure) and a still-"uncertain" operating environment.
Recurring phrases: "cost and productivity," "through the cycle," "world-class, low-cost resources," "financial flexibility." What they stopped saying: the aggressive multi-train Kemerton growth narrative of 2022–23 — replaced by "targeted growth capital focused on productivity." The tone shift from "survive" → "compete" → "grow (carefully)" tracks the price.
Lens 7 · Comps
Index/peer-set caveat: _index.json lists the electrification beat as EV/battery names (Tesla, CATL, BYD, LGES, QuantumScape). Those are demand-side comps, not valuation peers for a lithium producer. The correct peer set is lithium/specialty-chem upstream. Multiples below are `` and as-of varies (2026-05/06) — treat as directional, not precise:
| Company | Ticker | Mkt cap (USD) | EV/EBITDA | P/E | Note |
|---|
| Albemarle | ALB | ~$20B ≈118M] | n/a — not cleanly sourced (FY25 EBITDA $1.1B → ~18–20x on EV ~$21–22B; highly cycle-distorted) | neg FY25 (loss); fwd P/E meaningful only on a normalized number | Lowest-cost Western producer |
| SQM | SQM | ~$24.5B | ~18–28x | trailing ~43 / fwd ~20 | Atacama brine; Codelco control from 2031 |
| Ganfeng Lithium | 002460 / 1772.HK | ~$23.9B | n/a | n/a | Chinese vertically-integrated |
| Tianqi Lithium | 002466 / 9696.HK | n/a — not cleanly sourced | n/a | n/a | ALB's Greenbushes JV partner |
| Pilbara Minerals | PLS.AX | n/a | n/a | n/a | Pure spodumene (Pilgangoora) |
| Rio Tinto Lithium (ex-Arcadium) | within RIO | n/a (segment) | n/a | n/a | New major; $6.7B Arcadium deal closed Mar-2025 |
Honest verdict on comps: for a deep-cyclical, EV/EBITDA on trailing trough earnings is nearly meaningless (ALB optically ~18–20x because EBITDA is trough; on Q1'26 run-rate it collapses to single digits). The defensible cross-check is EV/resource-tonne and position on the cost curve, where ALB screens best-in-class among Western names. Precise per-company multiples beyond SQM are n/a; I will not fabricate them.
Lens 8 · Stock-Price Catalysts (5-yr, what moves >5%)
The pattern is overwhelmingly one variable: the lithium spot price. `` throughout:
- 2021–late 2022: lithium carbonate spike → ALB to a record >$320 (late 2022).
- 2023: lithium carbonate −80% → ALB −33.4% on the year, down >50% intra-year.
- 1H 2024: further −34%, to ~$79 (Aug 2024); the $2.2B mandatory-convert raise (Mar 2024) was itself a negative catalyst (dilution + distress signal).
- Late 2024: trough ~$110.
- Late 2025 → Jan 2026: battery-grade carbonate ~+95% (≈$13,400 → $26,300/t) on spodumene tightness + CATL Jianxiawo lepidolite delays → ALB re-rates.
- 2026 YTD: retrace from the spike (price settling ~$20/kg-equiv zone), ALB ~$159–170, analyst targets hiked (RBC $257, Vertical $224, Scotiabank $215).
What the market actually reacts to: lithium index prints, supply-side news (Chinese converter/lepidolite outages, mine delays), and ALB's own capital actions (raises, dividend, divestitures). Earnings beats matter far less than the price deck — this is a macro/commodity name dressed as a specialty chemical.
Phase C — Judge people & books
Lens 9 · Management
- CEO & Chairman: J. Kent Masters — CEO since April 2020; on the board since 2015 (joined via the Rockwood acquisition, where he was a non-employee director 2007–15).
- Track record: inherited the company near the top of the 2020s lithium build-out and is judged primarily on how he managed the bust. The scorecard is genuinely mixed:
- Credit: moved decisively on cost ($450M of improvements, exceeding target), cut capex 65%, raised $2.2B to shore up the balance sheet before it became forced, and executed a clean portfolio simplification (Ketjen + Eurecat sold for ~$670M, debt cut $1.3B). Barron's Top-25 CEO (2023).
- Debit: the Kemerton expansion (Trains 1–4) was greenlit into a price spike and is now largely idled/cancelled — destroyed capital. The mandatory convertible is dilutive and expensive (7.25%, converts March 2027 into 7.618–9.140 common shares per $1,000 unit → meaningful share-count overhang). These are textbook cyclical capital-allocation errors: build at the top, dilute at the bottom.
- Skin in the game: insider ownership is modest (professional-manager profile, not founder); precise insider % n/a (
insider-transactions.csv absent; would need DEF 14A).
- Capital-allocation history: the Rockwood deal (2015) that created the lithium franchise was excellent in hindsight; the 2022–23 growth capex was poorly timed; the 2024–26 retrenchment + deleveraging is competent damage control. Dividend: a 31-year increase streak (Dividend Aristocrat), held at $0.405/quarter through the loss year — paid $357M of dividends in 2025 against $692M FCF (~52% payout). The streak is a constraint, not a virtue, in a trough.
- Archetype: professional manager running a sovereign-entangled commodity asset. Implication: expect disciplined cost/cash stewardship and no heroics on the price view — exactly what they say.
Lens 10 · Forensic Red Flags
Acting as a forensic analyst over FY2025 + Q1'26 ``:
- Impairments (real, taken): $181.1M goodwill + $245.6M long-lived-asset impairments in FY2025; Ketjen written down to expected transaction value. These are clearing events, not hidden risk — but they confirm the 2022–23 capex was over-earned.
- Tax-asset valuation allowance: a full valuation allowance on all US deferred tax assets booked in Q4'25 (plus prior allowances in Australia/China). Drove the bizarre −55.2% Q4 effective rate and the 561% adjusted rate. Flag: a full DTA write-off is management signalling it cannot, under conservative accounting, assume near-term US taxable income — a sober read on the trough. It also means a future tax tailwind if profits return (the allowance can reverse).
- Equity-method / JV opacity: a large share of ALB's economic lithium comes through equity-method JVs (Talison/Greenbushes, MARBL/Wodgina). Consolidated revenue understates ALB's true lithium exposure, and JV-level pricing/cost detail is limited. Not fraud — but the headline P&L is not the whole economic picture; analysts must add back JV equity earnings.
- Adjusted-EBITDA add-backs: the gap between GAAP loss ($(510.6)M FY25) and adjusted EBITDA ($1,098.0M) is enormous — driven by impairments, restructuring, tax. Watch that "non-recurring" restructuring doesn't become recurring (FY24 had a $1.13B restructuring line; FY25 only $7.7M — the big charges have cleared, which is reassuring).
- Working-capital / cash quality: FY2025 OCF was flattered by a January-2025 customer prepayment and by inventory/receivable drawdowns (inventories $1,179M from $1,505M+; receivables $593.5M from $742.2M). Some of the ">100% cash conversion" is non-repeatable destocking. Flag for FY2026: cash conversion likely normalizes down.
- Mandatory-convert dilution: the $2.2B preferred converts March 1, 2027 into up to ~9.14 common shares per unit (46M depositary shares) — a known, dated share-count step-up that suppresses per-share metrics. Not hidden, but easy to forget in EPS models.
Regulatory findings:
- SEC Litigation Releases: none naming Albemarle 2021–2026 (EDGAR EFTS LR search clean).
- AAERs: none returned (note: the EFTS AAER query hit an HTTP 500 during the fetch, so AAER coverage is unconfirmed rather than affirmatively clean — minor caveat).
- Non-SEC enforcement (web search): Albemarle reached a 2023 settlement with the US DOJ/SEC over FCPA violations in its catalysts/refining business — agreeing to pay roughly $218M (DOJ + SEC disgorgement) for improper payments to foreign officials/intermediaries in Indonesia, India, China and elsewhere via third-party agents. This is the most material legal item and a genuine governance black mark, though it predates the current portfolio and was resolved with cooperation credit. (Item 3 Legal Proceedings from the 10-K not quoted —
ingest-filing.ts not run per wave constraint; recommend pulling it on the next non-wave pass.)
- Chile/CORFO: a long-running royalty/arbitration history with CORFO (incl. a ~$15M dispute settlement) — contractual/sovereign, not securities fraud.
Net forensic read: the accounting is aggressively cleaned (impairments + DTA allowance taken, not deferred), which is the opposite of a fraud pattern; the real risks are structural (JV opacity, prepayment-flattered cash, convert dilution) and reputational (the 2023 FCPA settlement), not manipulation.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028)
Anchor: ALB's own published price-sensitivity table — the single best forward framework, because it removes my guess on the price-to-EBITDA transfer function:
| Lithium price ($/kg LCE) | ~$10 (≈FY25 avg) | ~$20 (≈Q1'26 avg) | ~$30 (2021–25 avg) |
|---|
| Total net sales | $4.1–4.3B | $5.7–6.0B | $7.5–7.8B |
| Adjusted EBITDA | $0.9–1.0B | $2.4–2.6B | $4.2–4.4B |
(All scenarios assume flat volume after the 2025 destock, ~40% of salts on long-term contracts, spodumene ≈10% of LCE price.) This is the whole thesis in one table: EBITDA swings ~5x across a plausible price band ALB does not control.
EPS bridge (``, arithmetic shown). Using ~118M shares pre-conversion (rising to ~130M+ post-March-2027 mandatory convert), ~7.25%×$2.3B ≈ ~$167M preferred dividends until conversion, ~$1.8B net debt at ~5% ≈ ~$90M interest, ~25% normalized tax once the DTA allowance reverses, and treating adjusted EBITDA → adjusted net income with ~$450M D&A:
- FY2026 BASE (~$15/kg blended; between ALB's $10 and $20 cases): adj EBITDA ~$1.6–1.9B
→ less ~$450M D&A, ~$90M interest, ~$167M pref div, ~25% tax → adjusted EPS to common **~$5–7**. Q1'26 alone already printed $2.95 adjusted, so a full-year mid-$5s+ is reasonable if the price holds near Q1 levels. Wide because the input is wide.
- FY2026 BULL (~$20/kg holds): adj EBITDA ~$2.4–2.6B → adjusted EPS ~$10–13 ``.
- FY2026 BEAR (~$10/kg relapse): adj EBITDA ~$0.9–1.0B → adjusted EPS ~$0–2 ``, GAAP possibly near breakeven/loss.
- FY2027–28: volume CAGR mid-single-digits as Meishan/contract book grows; the swing remains price. Post-March-2027 the convert adds ~12M+ shares (≈10% dilution), capping per-share upside. n/a for any consensus EPS line; I will not fabricate one.
Per the unattended-watchlist rule, forecast.ts create was NOT run (no Brier forecast logged in breadth mode).
Lens 12 · Bull vs Bear
Bull case. ALB is the best-positioned Western lithium house going into a tightening market. Three legs: (1) lowest-quartile cost at Atacama + Greenbushes means it makes money where competitors bleed — survivorship is itself alpha in a consolidating industry (Arcadium gone to Rio, marginal converters shut). (2) The cost base is now fixed ($450M out, capex −65%, $1.3B debt repaid, net debt/EBITDA ~1.0x) right as the price inflected (+95% into Jan-2026) — operating leverage on the way up is violent, as Q1'26's +196% Energy-Storage EBITDA shows. (3) Secular demand — EV + grid storage keep lithium demand compounding; ALB lifted its own demand forecast. The contrarian bull point: the market is anchored on the 2023–24 bust and underpricing the speed of the operating-leverage snapback.
Bear case (permanent-impairment risks). (1) It's a price-taker on ~60% of volume with zero pricing moat — a return to ~$10/kg (the 2025 reality, and the persistent surplus risk from Chinese lepidolite + converter overcapacity) caps EBITDA at ~$0.9–1.0B against ~$1.8B net debt + a 7.25% preferred + an Aristocrat dividend it won't cut. (2) Sovereign/structural resource risk — the Chile CORFO royalty escalates to as high as 40% of price, reserves 15–25% for domestic preferential sale, and the broader Chilean "national lithium strategy" (Codelco control of SQM's Atacama from 2031; possible Atacama "absolute protection") tightens the screws on the lowest-cost tonnes over time. ALB doesn't even control Greenbushes (49% minority). (3) Dilution + over-build legacy — the mandatory convert dilutes ~10% in March 2027; Kemerton is a stranded-capital monument to top-of-cycle exuberance. Pre-mortem (18 months out, thesis broke): lithium relapsed to ~$10–12/kg on a fresh Chinese supply wave + softer EV demand; ALB's EBITDA halved back toward ~$1B; the convert diluted; the dividend got strained; the stock round-tripped to the $110–130 zone. Are multiples too high? On trough earnings, optically yes (~18–20x EV/EBITDA); on mid-cycle, no. The stock is literally a leveraged bet on the price deck — multiple debates miss the point.
Contrarian view (what the market refuses to see): both directions. Bulls ignore that the sovereign (Chile) is the long-term price-extractor on the very asset that is the moat — the royalty/strategy regime quietly socializes the up-cycle. Bears ignore that ALB has already taken the pain (impairments, DTA write-off, capex cut, deleveraging) and is now a cleaner, cheaper, lower-net-debt option on lithium than at any point in the bust — the asymmetry has improved even if the asset is unchanged.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull:
- Where revenue concentrates / what breaks it: ~60% index-linked lithium volume. A single variable — the lithium spot price, set at the margin by Chinese lepidolite and converter overcapacity ALB has no control over — determines the outcome. CATL restarting Jianxiawo, or a new African/Chinese supply wave, re-floods the market; the 2026 rally already shows signs of retracing (surplus ~40kt LCE noted by May-2026).
- Moat weaker than bulls think: a cost moat is not a pricing moat. In a commodity, the low-cost producer's "reward" for surviving the trough is more volume at the same low price — it doesn't earn excess returns until the cycle turns, and it can't make the cycle turn. And the lowest-cost tonnes (Chile) face a 40%-royalty / domestic-set-aside regime that taxes away the up-cycle.
- Most dangerous underestimated competitor: Rio Tinto Lithium (ex-Arcadium) — a deep-balance-sheet major that can out-invest ALB through the cycle and has explicit 200kt-by-2028 LCE ambitions; plus the Chinese integrated players (Ganfeng, Tianqi) who are ALB's JV partners and competitors simultaneously.
- Worst capital-allocation moves: Kemerton over-build (idled), the dilutive 7.25% mandatory convert at the bottom, and an Aristocrat dividend defended through a $510M loss year (capital that arguably should have gone to debt/optionality).
- Assumptions that must hold for today's ~$170: lithium settling ≥ ~$15–20/kg (mid-cycle), volume growing, no adverse Chile regulatory step-change, EV/ESS demand compounding, and the convert dilution already discounted. If lithium reverts to ~$10–12, EBITDA halves and the stock has 25–40% downside to the $110–130 zone ``.
- Single permanent-impairment scenario (plausibility): Chile materially tightens the Atacama regime (royalty/quota/"protection") and a structural lithium oversupply persists into the late 2020s — ALB's flagship asset gets re-rated as a high-tax, capped-margin resource. Plausibility: moderate-low on the catastrophic version, moderate on the slow-grind version (the royalty escalator and Codelco-style sovereign capture is already partly visible in SQM's path).
Lens 14 · Management Questions (ordered by information value)
- At a sustained ~$10/kg LCE, what is the cash-flow break-even after sustaining capex, interest, and the preferred dividend — and at what price would you cut the common dividend?
- Post the March-2027 mandatory-convert conversion, what is the fully-diluted share count, and how should we model per-share earnings power across your three price scenarios?
- On the Chile CORFO contract: what is the effective all-in royalty/take at $15, $20, and $30/kg, and how do you expect Chile's national lithium strategy (Codelco, Atacama protection) to affect Albemarle's quota and terms before 2043?
- You hold only 49% of Greenbushes and 50% of Wodgina — what is your true attributable lithium volume and cost vs the consolidated figures, and do you intend to increase control of these resources?
- What gives you confidence the $450M of cost-out is structural and not partly destock/prepayment timing that reverses in 2026?
- Under what price and balance-sheet conditions would you restart Kemerton Trains 1–2, and what return hurdle must clear before any new conversion capex?
- How much of FY2026 Energy-Storage volume is on long-term contracts with price floors, and what is the realized-price discount/premium to the spot index across the book?
- What normalized tax rate should we assume once the US DTA valuation allowance reverses, and what triggers the reversal?
- With Rio Tinto now a lithium major and Chinese integrated players as both partners and rivals, where do you expect to lose or gain share through 2028?
- What is your capital-allocation priority order today — debt, dividend, growth capex, buybacks — and at what net-debt/EBITDA do you flip from defense to offense?
- How exposed is Specialties/bromine to the Middle East supply-chain disruptions you flagged, and is that cost pressure transitory or structural?
- What is the realistic volume growth CAGR to 2030 given current sanctioned projects only (no new greenfield), and what would it take to accelerate?
- How do you think about Albemarle as a commodity-price proxy vs a specialty-chemicals compounder — and would you ever hedge lithium price to dampen the cyclicality the equity market punishes?
- What is your lithium demand forecast and the supply you expect to come offline/online at <$12/kg — i.e., where is the marginal-cost floor that supports prices?
- After the 2023 FCPA resolution, what specific controls changed, and how do you ensure the JV/third-party-agent structures that created that exposure are now clean?